IDH2 and acute myeloid leukemia: There are ongoing clinical trials assessing the role of IDH inhibition in combination with other modalities, such as in combination with induction/consolidation (NCT03839771), or in combination with CPX-351 in relapsed AML (NCT03825796) [106].